Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Myriad Genetics Inc (NASDAQ:MYGN)

BATS BZX Real-Time Price
As of 2:58pm ET
 -0.13 / -0.36%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through two segments: Diagnostics and Other. The Diagnostics segment engages in the provision of testing that is designed to assess the risk for developing disease later in life of the patient, identify the likelihood of responding to drug therapy and guide the dosing to ensure optimal treatment, or assess a the disease progression and disease recurrence of the patient. The Other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients. The company was founded by Walter A. Gilbert, Mark H. Skolnick and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake, UT.

Contact Information

Myriad Genetics, Inc.
320 Wakara Way
Salt Lake City Utah 84108
P:(801) 584-3600
Investor Relations:
(801) 584-1143



Other institutional57.55%
Mutual fund holders53.02%
Individual stakeholders4.26%

Top Executives

Mark C. CaponePresident, Chief Executive Officer & Director
Gary A. KingExecutive Vice President-International Operations
R. Bryan RiggsbeeChief Financial Officer, Treasurer & Executive VP
Robert Gardner HarrisonChief Information Officer
Jerry S. LanchburyChief Scientific Officer